Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2006-08-01
2006-08-01
Andres, Janet L. (Department: 1647)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S388100, C530S389100, C530S351000, C424S085500
Reexamination Certificate
active
07084257
ABSTRACT:
Selective binding agents of interferon-gamma (IFNγ) are provided by the invention. More particularly, the invention provides for antibodies and antigen binding domains which selectively bind to IFNγ and may be used to prevent or treat conditions relating to autoimmune and inflammatory diseases such as rheumatoid arthritis, systemic lupus erythematosus and multiple sclerosis. Nucleic acid molecules encoding said antibodies and antigen binding domains, and expression vectors and host cells for the production of same are also provided.
REFERENCES:
patent: 4474893 (1984-10-01), Reading
patent: 4634664 (1987-01-01), Oestberg
patent: 4666865 (1987-05-01), Chang et al.
patent: 4699880 (1987-10-01), Goldstein
patent: 5693761 (1997-12-01), Queen et al.
patent: 5985265 (1999-11-01), Kinstler et al.
patent: 6135941 (2000-10-01), Hillman et al.
patent: 6150584 (2000-11-01), Kucherlapati et al.
patent: 6255458 (2001-07-01), Lonberg et al.
patent: 6300129 (2001-10-01), Lonberg et al.
patent: 6312690 (2001-11-01), Edelman et al.
patent: 6329511 (2001-12-01), Vasquez et al.
patent: 6410824 (2002-06-01), Ehrhardt et al.
patent: 6444799 (2002-09-01), Ross
patent: 6498027 (2002-12-01), Van Es et al.
patent: 2002/0146750 (2002-10-01), Hoogenboom et al
patent: 2003/0056233 (2003-03-01), Ehrhardt et al.
patent: 0 154 316 (1989-09-01), None
patent: 0 401 384 (1996-03-01), None
patent: 11000174 (1999-01-01), None
patent: WO83/04053 (1983-11-01), None
patent: WO 91/02005 (1991-02-01), None
patent: WO 92/11018 (1992-07-01), None
patent: WO 99/55369 (1999-11-01), None
patent: WO 00/05268 (2000-02-01), None
patent: WO 00/06605 (2000-02-01), None
patent: WO 00/55351 (2000-09-01), None
patent: WO 01/09350 (2001-02-01), None
patent: WO 01/25492 (2001-04-01), None
patent: WO 01/34800 (2001-05-01), None
patent: WO 01/40306 (2001-06-01), None
patent: WO 01/57182 (2001-08-01), None
patent: WO 01/88132 (2001-11-01), None
patent: WO 01/98353 (2001-12-01), None
patent: WO 02/083872 (2002-10-01), None
patent: WO 02/094325 (2002-11-01), None
patent: WO 02/094879 (2002-11-01), None
patent: WO 02/102854 (2002-12-01), None
Morrison and Boyd, Organic Chemistry, 3rdedition, 1973, pp. 1134-1135.
Langer, “Interferon receptors”,Immunology Today, vol. 9, (12), pp. 393-400, (1988.
Skurkovich, “Successful first-time use of Antibodies to Interferon-• alone . . . ”,Int. J. Immunotherapy, vol. XIV (1) , pp. 23-32, (1998).
Gerez, Hyperinducible expression of the interferon-gamma (IFN-•) gene and its suppression in systemic lupus erthematosus (SLE),Clin. Exp. Immunol, vol. 109, pp. 296-303, (1997).
Cabilly, “Generation of antibody activity from immunoglobulin polypeptide chains produced inEscherichia coli”, Proc. Nalt. Acad. Sci., vol. 81, pp. 3273-3277, (1984).
Morrison, “Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains”,Proc. Natl. Acad. Sci., vol. 81, pp. 6851-6855, (1984).
Thakur and Landolfi, “A potent neutralizing monoclonal antibody can discriminate amongst IFNγ from various primates with greater specificity than can the human IFNγ receptor complex,”Mol Immunol, 36:1107-1115 (1999).
Takekoshi et al., “Human Monoclonal anti-HCMV neutralizing antibody from phage display libraries,”J Virol Methods, 74:89-98 (1998).
National Center for Biotechnology Information (NCBI) Accession No. 1AK5 [gi:2554679]. Inosine monophosphate dehydrogenase (Impdh) from Tritrichomonas foetus.
NCBI Acc. No. 1AYX [gi:3212473]; crystal structure of glucoamylase fromSaccharomycopsis fibuligeraat 1.7 angstroms.
NCBI Acc. No. 1B37—A [gi:6730082]; chain A, A 30 angstrom U-shaped catalytic tunnel in the crystal structure of polyamine oxidase.
GenBank Acc. No. BG756803; GenBank gi:14067456; dbEST Id: 8516861.
NCBI Acc. No. CAA03180; EMBL Acc. No. A49389.1; unnamed protein product [unidentified].
NCBI Acc. No. G00590 [gi:683994]; fruit fly STS Dm0315 clone 1 (3) 03670, sequence tagged site.
NCBI Acc. No. G01099 [gi:684503]; fruit fly STS Dm1782 clone DS00349 T7, sequence tagged site.
NCBI Acc. No. G37297 [gi:2996948]; SHGC-57484Homo sapiensSTS genomic, sequence tagged site.
NCBI Acc. No. G46898 [gi:4493189]; Z14933—1 zebrafish AB Danio rerio STS genomic clone z14933 5′, sequence tagged site.
NCBI Acc. No. G49294 [gi:4757467]; stcB33B7—3867 chromosome 22 genomic cloneHomo sapiensSTS genomic clone 33B7, sequence tagged site.
NCBI Acc. No. G56897 [gi:6122216]; SHGC-102633Homo sapiensSTS genomic, sequence tagged site.
NCBI Acc. No. G61782 [gi:6126951]; SHGC-89104Homo sapiensSTS genomic, sequence tagged site.
NCBI Acc. No. G72435 [gi:15146465]; MARC 7597-7598:992008547:1 SCF—porcine spleen Sus scrofa STS genomic, sequence tagged site.
NCBI Acc. No. G73246 [gi:17046947]; csnprev1l-pcr3-1Homo sapiensSTS genomic, sequence tagged site.
NCBI Acc. No. L25291 [gi:409036]; human polyreactive Ig rearranged mu-chain, V-D21/10-JH4, partial cds.
NCBI Acc. No. NP—274431 [gi:15677278]; crossover junction endodeoxyribonuclease RuvC [Neisseria meningitidis MC58].
NCBI Acc. No. X56592 [gi:36655]; human mRNA for immunoglobulin heavy chain (T14:Vh4-T14).
Boulianne, “Production of functional chimaeric mouse/human antibody”,Nature, vol. 312, pp. 643-646, (1984).
Neuberger, “A hapten-specific chimaeric IgE antibody with human physiological effector function”,Nature, vol. 314, pp. 268-270, (1985).
Liu, “Chimeric mouse-human IgG1 antibody that can mediate lysis of cancer cells”,Proc. Natl. Acad. Sci., vol. 84, pp. 3439-3443, (1987).
Wahl, “Improved radioimaging and tumor localization with monoclonal F(ab')2”,The Journal of Nuclear Medicine, vol. 24, (4), pp. 316-325, (1983).
Lewis, “Use of a novel mutagenesis strategy, optimized residue substitution, to decrease the off-rate of an anti-gp120 antibody”,Molecular Immnunology, vol. 32 )14—. pp. 1065-1072, (1995).
Marks, “By-passing immunization: Building high affinity human antibodies by chain shuffling”,Bio/Technology, vol. 10, pp. 779-783, (1992).
Kranz, “Restricted reassociation of heavy and light chains from hapten-specific monoclonal antibodies”,Proc. Natl. Acad Sci., vol. 78 (9), pp. 5807-5811, (1981).
Jones, “Replacing the complementarity-determining regions in a human antibody with those from a mouse”,Nature, vol. 321, pp. 522-525, (1986).
Riechmann, “Reshaping human antibodies for therapy”,Nature, vol. 332, pp. 323-327, (1988).
Verhoeyen, “Reshaping human antibodies: Grafting an Antilysozyme Activity”,Science, vol. 239, pp. 1534-1536, (1988).
Jakobovits, “Analysis of homozygous mutant chimeric mice: Deletion of the immunoglobulin heavychain joining region blocks B-cell development and antibody production”,Proc. Natl. Acad. Sci., vol. 90, pp. 2551-2555, (1993).
Jakobovits, “Germ-line transmission and expression of a human-derived yeast artificial chromosome”,Nature, vol. 362. pp. 255-258, (1993).
Br•ggemann, “Designer Mice: The production of human antibody repertoires in Transgenic animals”,Generation of Antibodies by Cell and Gene Immortalization, vol. 7, pp. 33-40, (1993).
Hoogenboom, “By-passing immunisation human antibodies form synthetic repertoires of germline VHGene segments rearranged in Vitro”,J. Mol. Biol., vol. 227, pp. 381-388, (1992).
Marks, “By-passing immunization Human antibodies from V-gene libraries displayed on Phage”,J. Mol. Biol., vol. 222, pp. 581-597, (1991).
Deshpande Rajendra V.
Tsai Mei-Mei
Amgen Inc.
Andres Janet L.
Seharaseyon Jegatheesan
Sweeney Rosemary
LandOfFree
Fully human antibody Fab fragments with human... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Fully human antibody Fab fragments with human..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fully human antibody Fab fragments with human... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3671624